Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fuso Pharmaceutical Industries's EBIT per Share for the
six
months ended in Mar. 2026 was 円177.79.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円323.95.
During the past 12 months, the average EBIT per Share Growth Rate of Fuso Pharmaceutical Industries was -36.10% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 7.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 8.90% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 23.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Fuso Pharmaceutical Industries's EBIT per Share or its related term are showing as below:
TSE:4538'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -57.3 Med: 7.1 Max: 101.7
Current: 7.1
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Fuso Pharmaceutical Industries was 101.70% per year. The lowest was -57.30% per year. And the median was 7.10% per year.
TSE:4538's 3-Year EBIT Growth Rate is ranked worse than 50.43% of 813
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs TSE:4538: 7.10
Fuso Pharmaceutical Industries (TSE:4538) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Fuso Pharmaceutical Industries EBIT per Share Related Terms
Fuso Pharmaceutical Industries EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fuso Pharmaceutical Industries EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円323.95
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fuso Pharmaceutical Industries (TSE:4538) has a EBIT per Share of 円323.95 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Fuso Pharmaceutical Industries and its competitors. According to the industry distribution chart, Fuso Pharmaceutical Industries ranks #410 out of 813 companies in the Drug Manufacturers industry, placing it in the top 50.4%.
Is Fuso Pharmaceutical Industries' EBIT per Share too high?
Fuso Pharmaceutical Industries' current EBIT per Share is 円323.95. Based on the distribution chart, Fuso Pharmaceutical Industries ranks #410 out of 813 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Fuso Pharmaceutical Industries has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fuso Pharmaceutical Industries' EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Fuso Pharmaceutical Industries ranks #410 out of 813 companies for EBIT per Share. This places Fuso Pharmaceutical Industries in the lower half of its industry. The industry median EBIT per Share is 7.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Fuso Pharmaceutical Industries and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fuso Pharmaceutical Industries's current EBIT per Share is 円323.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fuso Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Fuso Pharmaceutical Industries (TSE:4538) is currently considered Modestly Undervalued. The stock's GF Value™ is 円2,556.06, compared to a current price of 円2,194.00 — trading 14.2% below its estimated fair value. The current EBIT per Share is 円323.95. Fuso Pharmaceutical Industries' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Fuso Pharmaceutical Industries (TSE:4538), the current EBIT per Share is 円323.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fuso Pharmaceutical Industries (TSE:4538) Overvalued in 2026?
Based on GuruFocus' analysis, Fuso Pharmaceutical Industries stock appears to be undervalued.
The current stock price of 円2,194.00 is trading 14.2% below its estimated GF Value™ of 円2,556.06.
GuruFocus considers Fuso Pharmaceutical Industries to be Modestly Undervalued.
Key valuation signals for TSE:4538:
EBIT per Share: 円323.95
GF Value™: 円2,556.06 vs. price of 円2,194.00 (14.2% below fair value)
No single metric tells the full story. See the TSE:4538 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fuso Pharmaceutical Industries Business Description
Fuso Pharmaceutical Industries Ltd. is engaged in the manufacture and sale of pharmaceuticals and medical equipment. The company's main products are transfusion fluid and artificial kidney dialysis fluid. Company also includes real estate segment.
51GF Score
Get the complete analysis for TSE:4538
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4538 has been successfully added to your 
